159 related articles for article (PubMed ID: 16375688)
1. Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.
Dainese E; Gasperi V; Maccarrone M
Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):709-14. PubMed ID: 16375688
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase: a potential target for next generation therapeutics.
Maccarrone M
Curr Pharm Des; 2006; 12(6):759-72. PubMed ID: 16472164
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Hwang J; Adamson C; Butler D; Janero DR; Makriyannis A; Bahr BA
Life Sci; 2010 Apr; 86(15-16):615-23. PubMed ID: 19527737
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines.
Mulder AM; Cravatt BF
Biochemistry; 2006 Sep; 45(38):11267-77. PubMed ID: 16981687
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase inhibitors--progress and potential.
Khanna IK; Alexander CW
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):545-58. PubMed ID: 21631410
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
12. Three-Dimensional Quantitative Structure-Activity Relationships (3D-QSAR) on a Series of Piperazine-Carboxamides Fatty Acid Amide Hydrolase (FAAH) Inhibitors as a Useful Tool for the Design of New Cannabinoid Ligands.
Lorca M; Valdes Y; Chung H; Romero-Parra J; Pessoa-Mahana CD; Mella J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117309
[TBL] [Abstract][Full Text] [Related]
13. Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent.
Nicolussi S; Chicca A; Rau M; Rihs S; Soeberdt M; Abels C; Gertsch J
Biochem Pharmacol; 2014 Dec; 92(4):669-89. PubMed ID: 25283614
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling.
Egertová M; Cravatt BF; Elphick MR
Neuroscience; 2003; 119(2):481-96. PubMed ID: 12770562
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
16. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
Vandevoorde S; Lambert DM
Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.
Nucci C; Gasperi V; Tartaglione R; Cerulli A; Terrinoni A; Bari M; De Simone C; Agrò AF; Morrone LA; Corasaniti MT; Bagetta G; Maccarrone M
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):2997-3004. PubMed ID: 17591864
[TBL] [Abstract][Full Text] [Related]
19. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Vandevoorde S
Curr Top Med Chem; 2008; 8(3):247-67. PubMed ID: 18289091
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
